Senses Disorder TRIZ Cases

Chemical modifications of the probucol scaffold enhance water solubility and bioavailability while mitigating QT interval prolongation risks.

A humanized antibody binds tissue factor to block oncogenic signaling pathways without interfering with coagulation factors.

Monospecific heavy chain only antibodies bind angiopoietin-2 to inhibit abnormal blood vessel growth in the eye.

Segmenting the otoferlin gene into viral vectors bypasses packaging limits, restoring hearing by enabling full-length protein expression in inner ear cells.

Engineered monoclonal antibodies block RGM A binding to Neogenin receptors, resolving specificity trade-offs to enhance neuronal repair.

Ambroxol eye drop formulations stimulate tear film production, reducing inflammation and providing extended relief for dry eye disease patients.

Modular imidazole and thiazole structures inhibit TGF-beta signaling, increasing muscle tissue volume and bone mass while improving glucose homeostasis.

Novel 1,2-dihydroquinoline derivatives incorporate phenylchalcogeno alkyl and ester-introduced phenyl substituents to modulate glucocorticoid receptors.

Helminth egg fraction compositions promote wound healing by stimulating type 2 immune responses while minimizing fibrosis and hepatic damage.

Cyclodextrin suppresses pyrroloquinoline quinone deposition in acidic beverages containing ascorbic acid through inclusion complex formation.

Kalium channel rhodopsins provide rapid neuronal silencing by switching from cation channels to potassium conductance, resolving slow kinetics in optogenetics.

Antisense oligonucleotides target natural antisense transcripts to modulate pancreatic developmental gene expression levels in patient cells.

Segmented IL-4 peptides inhibit macrophage activation, reducing inflammatory responses while avoiding recombinant protein storage denaturation.

A detoxified E. coli heat-labile enterotoxin mutant induces anti-allergic responses via mucosal administration.

4-amino-pyrimidine derivatives target histamine H4 receptors with high affinity, reducing side effects from non-specific binding.

A contact lens coating uses 3D capillary structures to modulate medicament release rates through controlled diffusion paths.

Lysine mimetic compounds resolve peptide instability and short half-life by modifying molecular structure to sustain pharmacological activity.

Upregulating ABCA1 transporter protein on macrophages to enhance cholesterol efflux.

1,2,4-oxadiazole derivatives act as liver X receptor agonists to lower meibomian gland secretion melting points and resolve obstruction.

Primary amine compounds bind toxic all-trans-retinal via reversible Schiff bases, preventing retinal degeneration without compromising visual cycle function.

Dithiol compounds reverse disulfide bond formation in aging lenses, restoring accommodative amplitude while reducing opacity.

Substituted aminopyrimidines bind VCAM-1 to inhibit VLA-4 mediated leukocyte adhesion, improving bioavailability for treating inflammatory diseases.

Bicyclic heterocyclyl compounds inhibit multiple protein kinases including VEGF-R2, addressing inadequate coverage of kinase types in existing treatments.

Hydrogen bond surrogate helices mimic the HIF-1α transactivation domain to block p300/CBP binding, avoiding side effects from current inhibitors.

Chiral substitution patterns on the piperidine ring enhance therapeutic efficacy while minimizing gastrointestinal side effects.

Recombinant transferrin-tumstatin fusion protein targets activated endothelial cells to inhibit neovascularization.

Reducing transferrin receptor binding affinity prevents rapid saturation, enabling enhanced brain uptake and prolonged therapeutic concentrations.

Codon optimization of the RPGR gene eliminates mutation hotspots in repetitive regions, enabling reliable large-scale AAV vector manufacturing.

Segmented dapagliflozin propylene glycol hydrate formulation with bulking agents and binders for immediate oral release.

Anti-carboxyethylpyrrole antibodies neutralize CEP protein adducts to block angiogenic stimulation.

A lipid-based ophthalmic emulsion uses mucoadhesive polymers to enhance ocular surface hydration.

Anhydrous ABSD-Lysine salt phase forms via ionic bonding to boost thermal stability and solubility.

Fluid formulations bond to ocular tissue via covalent or non-covalent interactions to extend residence time in the suprachoroidal space.

Piezoelectric devices generate micro-dose droplet streams to deliver atropine, reducing overflow and improving stability.

Clonal expansion of residual undifferentiated pluripotent stem cells using laminin-521 and E-cadherin substrates with ROCK inhibitors.

Bicyclic aza-amide derivatives inhibit FKBP51 and FKBP52 without immunosuppressive activity, resolving the toxicity trade-off of traditional inhibitors.

Acetylcholinesterase inhibitors target the nervous system of Demodex mites, resolving persistent inflammation and meibomian gland dysfunction.

Mutating halorhodopsin shifts activation to red light, enabling multi-color neural silencing with lower power requirements.

Replacing xenogeneic feeder cells with a defined serum-free medium using EGF and ROCK inhibitors eliminates safety risks while maintaining cell viability.

Monomycolyl glycerol adjuvants activate dendritic cells to induce strong Th1 immunity, resolving the Th2 bias of conventional aluminum-based vaccines.

Standardized herbal extracts down-regulate vascular endothelial growth factor to treat neovascular age-related macular degeneration.

Enzymatic dissociation and size fractionation isolate pure RPE progenitors, eliminating manual picking and boosting yields up to 90 times.

New substituted quinolines inhibit Syk kinase activity to treat respiratory and allergic diseases.

Novel isoquinoline-6-sulfonamide derivatives reduce intraocular pressure and blood pressure.

FK506 analogs potentiate BMP signaling by displacing FKBP12, eliminating the nephrotoxicity caused by calcineurin inhibition.

Crystalline forms E and C of Compound 1 inhibit abnormal angiogenesis through specific solvent-based preparation methods.

Subretinal delivery of rAAV vectors expressing human RS1 protein restores retinal structure and photoreceptor function.

Etanercept inhibits TNFα to relieve fatigue and pain, addressing the lack of effective treatments for enthesitis-type fibromyalgia.

Small molecule imidazopyridazine derivatives resolve the trade-off between macromolecular reliability and structural versatility by inhibiting TNFα binding.